Nathan J. Pertsch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nathan J. Pertsch has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
Sepehr Sani
Department of Neurosurgery Rush University Medical Center Chicago IL USA
4 shared publicationsDustin Kim
Department of Neurosurgery Rush University Medical Center Chicago IL USA
3 shared publications- Kazuki Sakakura
Department of Neurosurgery, Rush University Medical Center, Chicago, Illinois, USA
3 shared publications Shama Patel
Department of Neurosurgery Rush University Medical Center Chicago IL USA
3 shared publicationsEmilija Sagaityte
The Warren Alpert School of Medicine, Brown University, Providence, Rhode Island, USA
2 shared publicationsJacob Mazza
2 shared publications
Latest Publications
- Open Access
- 9 August 2026
- Published by Wiley in Movement Disorders Clinical Practice
Staged Bilateral Magnetic Resonance‐Guided Focused Ultrasound for Treating Essential Tremor: Systematic Review and Meta‐Analysis
Background: Unilateral magnetic resonance guided focused ultrasound (MRgFUS) thalamotomy reduces tremor in essential tremor, yet disability often persists on the untreated side. The added benefit and safety of a staged contralateral lesion remain uncertain. Objective: The aim was to evaluate the efficacy and safety of staged bilateral MRgFUS thalamotomy for essential tremor. Methods: We searched MEDLINE, EMBASE, Web of Science, Cochrane CENTRAL, Scopus, ClinicalTrials.gov , and World Health Organization International Clinical Trials Registry Platform from inception to April 12, 2026 (PROSPERO CRD420251027624). Eligible studies were staged bilateral MRgFUS with Clinical Rating Scale for Tremor outcomes and adverse events, and at least 3 months of follow up. Two reviewers extracted data per Preferred Reporting Items for Systematic Reviews and Meta‐Analyses. The primary outcome was the standardized mean difference (SMD) in tremor severity from pre‐ to post‐second procedure. Safety outcomes were pooled 3‐month adverse event proportions using random effects. Risk of bias was assessed with Newcastle‐Ottawa Scale and Risk of Bias in Non‐randomized Studies of Interventions; certainty was graded with Grading of Recommendations Assessment, Development, and Evaluation. Results: Nine studies were included in the systematic review, of which seven cohorts (n = 149) were included in the meta‐analysis. The pooled SMD was −1.91 (95% confidence intervals, −2.19 to −1.63; I 2 = 0%), indicating consistent, large‐magnitude tremor reduction across all seven cohorts. Three‐month adverse events included sensory changes (28.8%), gait disturbance (27.5%), dysarthria (22.0%), taste changes (21.7%), dysphagia (18.4%), and ataxia (11.3%). All studies were single‐arm and non‐randomized with moderate to serious risk of bias, and certainty was very low. Conclusions: Staged bilateral MRgFUS yielded clinically meaningful tremor reduction with predominantly mild adverse events at 3 months. Given very low certainty, findings are hypothesis‐generating and support‐controlled studies with blinded assessment and longer follow‐up.
- 9 August 2026
- Published by Wiley in Movement Disorders Clinical Practice
Open AccessStaged Bilateral Magnetic Resonance‐Guided Focused Ultrasound for Treating Essential Tremor: Systematic Review and Meta‐Analysis
Background: Unilateral magnetic resonance guided focused ultrasound (MRgFUS) thalamotomy reduces tremor in essential tremor, yet disability often persists on the untreated side. The added benefit and safety of a staged contralateral lesion remain uncertain. Objective: The aim was to evaluate the efficacy and safety of staged bilateral MRgFUS thalamotomy for essential tremor. Methods: We searched MEDLINE, EMBASE, Web of Science, Cochrane CENTRAL, Scopus, ClinicalTrials.gov , and World Health Organization International Clinical Trials Registry Platform from inception to April 12, 2026 (PROSPERO CRD420251027624). Eligible studies were staged bilateral MRgFUS with Clinical Rating Scale for Tremor outcomes and adverse events, and at least 3 months of follow up. Two reviewers extracted data per Preferred Reporting Items for Systematic Reviews and Meta‐Analyses. The primary outcome was the standardized mean difference (SMD) in tremor severity from pre‐ to post‐second procedure. Safety outcomes were pooled 3‐month adverse event proportions using random effects. Risk of bias was assessed with Newcastle‐Ottawa Scale and Risk of Bias in Non‐randomized Studies of Interventions; certainty was graded with Grading of Recommendations Assessment, Development, and Evaluation. Results: Nine studies were included in the systematic review, of which seven cohorts (n = 149) were included in the meta‐analysis. The pooled SMD was −1.91 (95% confidence intervals, −2.19 to −1.63; I 2 = 0%), indicating consistent, large‐magnitude tremor reduction across all seven cohorts. Three‐month adverse events included sensory changes (28.8%), gait disturbance (27.5%), dysarthria (22.0%), taste changes (21.7%), dysphagia (18.4%), and ataxia (11.3%). All studies were single‐arm and non‐randomized with moderate to serious risk of bias, and certainty was very low. Conclusions: Staged bilateral MRgFUS yielded clinically meaningful tremor reduction with predominantly mild adverse events at 3 months. Given very low certainty, findings are hypothesis‐generating and support‐controlled studies with blinded assessment and longer follow‐up.
- Open Access
- 12 February 2026
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 35 (4) , 108588
Mechanical thrombectomy and decompressive hemicraniectomy trends for acute ischemic stroke: A nationwide analysis
- 12 February 2026
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 35 (4) , 108588
Open AccessMechanical thrombectomy and decompressive hemicraniectomy trends for acute ischemic stroke: A nationwide analysis
- 29 October 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (7) , 1653-1661
Tremor Control and Patient Reported Outcomes after Bilateral Focused Ultrasound Thalamotomy for Essential Tremor
Background: Staged bilateral magnetic resonance‐guided focused ultrasound (MRgFUS) thalamotomy is FDA approved to treat essential tremor (ET), but patient‐reported outcomes and satisfaction data are limited. Objectives: We present tremor outcomes, patient‐reported adverse effects, and satisfaction in a cohort of 30 treated patients. Methods: Patients underwent staged bilateral MRgFUS thalamotomy from 2020 to 2024, with minimum three‐months of follow‐up. Upper extremity tremor was assessed using the Clinical Rating Scale for Tremor Part B. Patients were asked directly about speech changes, sensory changes, gait disturbance, dysphagia, taste changes, ataxia, weakness, and satisfaction with bilateral treatment. Results: Thirty patients underwent staged bilateral MRgFUS, of which 25 (83%) have 6 months, 20 (67%) have 12 months, and 10 (33%) have 24+ months of follow‐up. Tremor severity at baseline was similar bilaterally and was significantly improved bilaterally by treatment ( P < 0.001); however, not as greatly on the second treated side. Twenty‐six patients (87%) reported at least one new mild or moderate adverse effect after bilateral treatment; no severe adverse effects were reported. Notably, at 12 months 55% reported persistent speech changes, 30% reported persistent sensory changes, and 20% reported persistent gait disturbance. At 3 and 6 months of follow‐up, more than 80% of patients reported that they would repeat second‐side treatment in retrospect, but this declined to 67% at 12 months, and 60% at 24+ months. Conclusion: Significant bilateral tremor control was achieved after bilateral MRgFUS thalamotomy for ET, but rates of some adverse effects were higher than previously reported.
- 29 October 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (7) , 1653-1661
Tremor Control and Patient Reported Outcomes after Bilateral Focused Ultrasound Thalamotomy for Essential Tremor
Background: Staged bilateral magnetic resonance‐guided focused ultrasound (MRgFUS) thalamotomy is FDA approved to treat essential tremor (ET), but patient‐reported outcomes and satisfaction data are limited. Objectives: We present tremor outcomes, patient‐reported adverse effects, and satisfaction in a cohort of 30 treated patients. Methods: Patients underwent staged bilateral MRgFUS thalamotomy from 2020 to 2024, with minimum three‐months of follow‐up. Upper extremity tremor was assessed using the Clinical Rating Scale for Tremor Part B. Patients were asked directly about speech changes, sensory changes, gait disturbance, dysphagia, taste changes, ataxia, weakness, and satisfaction with bilateral treatment. Results: Thirty patients underwent staged bilateral MRgFUS, of which 25 (83%) have 6 months, 20 (67%) have 12 months, and 10 (33%) have 24+ months of follow‐up. Tremor severity at baseline was similar bilaterally and was significantly improved bilaterally by treatment ( P < 0.001); however, not as greatly on the second treated side. Twenty‐six patients (87%) reported at least one new mild or moderate adverse effect after bilateral treatment; no severe adverse effects were reported. Notably, at 12 months 55% reported persistent speech changes, 30% reported persistent sensory changes, and 20% reported persistent gait disturbance. At 3 and 6 months of follow‐up, more than 80% of patients reported that they would repeat second‐side treatment in retrospect, but this declined to 67% at 12 months, and 60% at 24+ months. Conclusion: Significant bilateral tremor control was achieved after bilateral MRgFUS thalamotomy for ET, but rates of some adverse effects were higher than previously reported.
- 26 October 2025
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 259, 109213
An exploratory study on surgical planning of single trajectory deep brain stimulation of ventral intermediate nucleus and subthalamic nucleus
- 26 October 2025
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 259, 109213
An exploratory study on surgical planning of single trajectory deep brain stimulation of ventral intermediate nucleus and subthalamic nucleus
- Open Access
- 23 September 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (10) , 1030
Lumbosacral Endoscopic Ventral–Dorsal Rhizotomy: A Novel Approach for Tone Reduction
Objective: Neurosurgical interventions for medically refractory hypertonia (MRH) benefit both patients and their caregivers. Concurrent severe rotatory scoliosis and fusion constructs can make traditional microsurgical rhizotomy and navigated radiofrequency ablation (RFA) peripheral rhizotomy technically infeasible. We report the first case series of lumbosacral endoscopic ventral–dorsal rhizotomy (eVDR) in patients with MRH, and highlight this novel, minimally invasive, safe, and effective technique. Material and Methods: We retrospectively reviewed our single institution series of four patients with advanced hypertonia, gross motor function classification scale (GMFCS) 5, and severe rotatory scoliosis who underwent an eVDR using a flexible endoscope. We report demographics, operative characteristics, and outcomes. Results: Four patients underwent bilateral L1-S1 eVDR. Two patients had spastic quadriplegia and two had mixed spastic and dystonic hypertonia. Mean operative time was 225 ± 11 min and mean estimated blood loss (EBL) was 28.8 ± 26.2 mLs. Average length of stay was 2.75 days (range = 1–5 days), and average follow-up was 5.75 months (range = 3–9 months). All patients had significant decrease in bilateral lower extremity modified Ashworth Scale (mAS) scores (median decrease = 3, interquartile range [IQR] = 1; Wilcoxon rank-sum test z = −2.3, p = 0.02). The median decrease in Barry–Albright Dystonia Scale (BADS) scores for both patients with dystonia was 8 (IQR = 0). Two patients had minor perioperative events; none required additional surgery. All parents reported improvement in caregiving metrics. Conclusions: eVDR offers a safe and effective approach for tone reduction in patients with MRH and severe rotatory scoliosis and/or fusion hardware, which disallows traditional approaches.
- 23 September 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (10) , 1030
Open AccessLumbosacral Endoscopic Ventral–Dorsal Rhizotomy: A Novel Approach for Tone Reduction
Objective: Neurosurgical interventions for medically refractory hypertonia (MRH) benefit both patients and their caregivers. Concurrent severe rotatory scoliosis and fusion constructs can make traditional microsurgical rhizotomy and navigated radiofrequency ablation (RFA) peripheral rhizotomy technically infeasible. We report the first case series of lumbosacral endoscopic ventral–dorsal rhizotomy (eVDR) in patients with MRH, and highlight this novel, minimally invasive, safe, and effective technique. Material and Methods: We retrospectively reviewed our single institution series of four patients with advanced hypertonia, gross motor function classification scale (GMFCS) 5, and severe rotatory scoliosis who underwent an eVDR using a flexible endoscope. We report demographics, operative characteristics, and outcomes. Results: Four patients underwent bilateral L1-S1 eVDR. Two patients had spastic quadriplegia and two had mixed spastic and dystonic hypertonia. Mean operative time was 225 ± 11 min and mean estimated blood loss (EBL) was 28.8 ± 26.2 mLs. Average length of stay was 2.75 days (range = 1–5 days), and average follow-up was 5.75 months (range = 3–9 months). All patients had significant decrease in bilateral lower extremity modified Ashworth Scale (mAS) scores (median decrease = 3, interquartile range [IQR] = 1; Wilcoxon rank-sum test z = −2.3, p = 0.02). The median decrease in Barry–Albright Dystonia Scale (BADS) scores for both patients with dystonia was 8 (IQR = 0). Two patients had minor perioperative events; none required additional surgery. All parents reported improvement in caregiving metrics. Conclusions: eVDR offers a safe and effective approach for tone reduction in patients with MRH and severe rotatory scoliosis and/or fusion hardware, which disallows traditional approaches.
- 3 July 2025
- Published by Taylor & Francis in The Neurodiagnostic Journal
- Vol. 65 (4) , 287-307
Neuromodulation for Epilepsy
Epilepsy surgery encompasses a wide range of procedures aimed at reducing or eliminating seizures. In these procedures, there are opportunities to employ intraoperative neurophysiology to map the epileptic focus and accurately identify functional areas of the brain. In cases of drug-resistant epilepsy where onset is diffuse, multifocal, or in an eloquent region of the brain, resection is not possible, and neuromodulation can be considered to reduce the seizure burden. While resective or ablative therapy aims to be curative, neuromodulation techniques for epilepsy are generally considered palliative. The goal of neuromodulation is to use an implantable device with electrodes and a pulse generator to use electrical energy to interfere with the nervous system. Three neuromodulation modalities have been approved by the United States FDA for epilepsy: vagus nerve stimulation, deep brain stimulation of the anterior nucleus of the thalamus, and responsive neurostimulation. While rates of seizure freedom with neuromodulation are lower than with resection of an epileptogenic focus, many patients experience >50% reduction in seizures, and results improve with time, suggesting both acute and chronic benefits with these therapies.
- 3 July 2025
- Published by Taylor & Francis in The Neurodiagnostic Journal
- Vol. 65 (4) , 287-307
Neuromodulation for Epilepsy
Epilepsy surgery encompasses a wide range of procedures aimed at reducing or eliminating seizures. In these procedures, there are opportunities to employ intraoperative neurophysiology to map the epileptic focus and accurately identify functional areas of the brain. In cases of drug-resistant epilepsy where onset is diffuse, multifocal, or in an eloquent region of the brain, resection is not possible, and neuromodulation can be considered to reduce the seizure burden. While resective or ablative therapy aims to be curative, neuromodulation techniques for epilepsy are generally considered palliative. The goal of neuromodulation is to use an implantable device with electrodes and a pulse generator to use electrical energy to interfere with the nervous system. Three neuromodulation modalities have been approved by the United States FDA for epilepsy: vagus nerve stimulation, deep brain stimulation of the anterior nucleus of the thalamus, and responsive neurostimulation. While rates of seizure freedom with neuromodulation are lower than with resection of an epileptogenic focus, many patients experience >50% reduction in seizures, and results improve with time, suggesting both acute and chronic benefits with these therapies.
- 5 March 2025
- Published by Wolters Kluwer Health in Operative Neurosurgery
- Vol. 29 (4) , 484-494
Dual-Lesion Magnetic Resonance–Guided Focused Ultrasound Thalamotomy of the Ventralis Intermedius Nucleus and Ventralis Oralis Anterior and Posterior Nuclei for the Treatment of Tremor-Dominant Parkinson's Disease: Outcomes in 6 Treated Cases
BACKGROUND AND OBJECTIVES: The ventralis intermedius nucleus of the thalamus (Vim) is the preferred target in magnetic resonance–guided focused ultrasound (MRgFUS) for tremor-dominant Parkinson’s disease (TdPD), but some patients with TdPD have persistent tremor after Vim thalamotomy. Basal ganglia outflow through the ventralis oralis anterior and posterior (Voa/p) may be responsible. We present 6 cases with dual Vim and Voa/p MRgFUS thalamotomies for TdPD resistant to Vim treatment. METHODS: Six patients with TdPD underwent Vim MRgFUS thalamotomy with persistent intraprocedural tremors (resting 5 patients and/or action tremors 1 patient), who then underwent Voa/p thalamotomy during the same procedure. Demographic and treatment information was collected. Tremor was evaluated using the Clinical Rating Scale for Tremor (CRST)-A and CRST-B. RESULTS: Six patients were included in the study. The mean age was 71.5 years (SD = 2.7), 5 were male (83.3%), 4 had right-sided treatments (66.7%), and 1 had a repeat treatment (16.7%). The mean follow-up was 11 months (range 6-18 months). Mean Vim lesion coordinates from the posterior commissure were X = 13.9 mm, Y = 7.5 mm, and Z = 2 mm. Voa/p were targeted by moving approximately 3 to 5 mm anterior and 3 mm medial to the initial Vim lesion. Mean Voa/p lesion coordinates were X = 11.7 mm, Y = 11.3 mm, and Z = 2.3 mm. Five patients with resting tremor had improved postural/action tremor after Vim thalamotomy (mean CRST-B 8.8 improved to 0.4) but unsatisfactory control of resting tremor. After Voa/p thalamotomy, resting tremor improved in all 5 patients (mean CRST-A hand score 3.6 improved to 0.0). For the patient without resting tremor, postural/action tremor improved after Voa/p thalamotomy (CRST 3 improved to 1). All improvements were sustained at last follow-up except for 1 patient, who regressed to preoperative postural/action and resting tremor by 6 months. At last follow-up, 2 patients reported speech (33.3%) and 3 patients reported balance/gait (50%) changes. CONCLUSION: Patients with TdPD with tremor refractory to Vim MRgFUS thalamotomy may benefit from a secondary lesion in Voa/p although incidence of adverse effects may be increased.
- 5 March 2025
- Published by Wolters Kluwer Health in Operative Neurosurgery
- Vol. 29 (4) , 484-494
Dual-Lesion Magnetic Resonance–Guided Focused Ultrasound Thalamotomy of the Ventralis Intermedius Nucleus and Ventralis Oralis Anterior and Posterior Nuclei for the Treatment of Tremor-Dominant Parkinson's Disease: Outcomes in 6 Treated Cases
BACKGROUND AND OBJECTIVES: The ventralis intermedius nucleus of the thalamus (Vim) is the preferred target in magnetic resonance–guided focused ultrasound (MRgFUS) for tremor-dominant Parkinson’s disease (TdPD), but some patients with TdPD have persistent tremor after Vim thalamotomy. Basal ganglia outflow through the ventralis oralis anterior and posterior (Voa/p) may be responsible. We present 6 cases with dual Vim and Voa/p MRgFUS thalamotomies for TdPD resistant to Vim treatment. METHODS: Six patients with TdPD underwent Vim MRgFUS thalamotomy with persistent intraprocedural tremors (resting 5 patients and/or action tremors 1 patient), who then underwent Voa/p thalamotomy during the same procedure. Demographic and treatment information was collected. Tremor was evaluated using the Clinical Rating Scale for Tremor (CRST)-A and CRST-B. RESULTS: Six patients were included in the study. The mean age was 71.5 years (SD = 2.7), 5 were male (83.3%), 4 had right-sided treatments (66.7%), and 1 had a repeat treatment (16.7%). The mean follow-up was 11 months (range 6-18 months). Mean Vim lesion coordinates from the posterior commissure were X = 13.9 mm, Y = 7.5 mm, and Z = 2 mm. Voa/p were targeted by moving approximately 3 to 5 mm anterior and 3 mm medial to the initial Vim lesion. Mean Voa/p lesion coordinates were X = 11.7 mm, Y = 11.3 mm, and Z = 2.3 mm. Five patients with resting tremor had improved postural/action tremor after Vim thalamotomy (mean CRST-B 8.8 improved to 0.4) but unsatisfactory control of resting tremor. After Voa/p thalamotomy, resting tremor improved in all 5 patients (mean CRST-A hand score 3.6 improved to 0.0). For the patient without resting tremor, postural/action tremor improved after Voa/p thalamotomy (CRST 3 improved to 1). All improvements were sustained at last follow-up except for 1 patient, who regressed to preoperative postural/action and resting tremor by 6 months. At last follow-up, 2 patients reported speech (33.3%) and 3 patients reported balance/gait (50%) changes. CONCLUSION: Patients with TdPD with tremor refractory to Vim MRgFUS thalamotomy may benefit from a secondary lesion in Voa/p although incidence of adverse effects may be increased.
- 1 October 2024
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. -1 (aop) , 1-7
Frailty and outcomes after unilateral MRI-guided focused ultrasound thalamotomy for tremor
OBJECTIVE: Frailty is recognized as an important predictor of neurointerventional outcomes. MRI-guided focused ultrasound (MRgFUS) thalamotomy is a treatment option for patients with refractory essential tremor (ET) and tremor-dominant Parkinson’s disease (TdPD). The aim of this study was to evaluate whether frailer MRgFUS thalamotomy patients had worse tremor outcomes or more complications. METHODS: The authors performed a cohort analysis of patients treated with MRgFUS between 2020 and 2023. Inclusion criteria were unilateral MRgFUS thalamotomy for ET or TdPD with available follow-up data (minimum 3-month follow-up). Frailty was assessed using the 11-item modified frailty index (mFI-11), which includes 11 medical comorbidities. Tremor outcomes were assessed using the Clinical Rating Scale for Tremor Part B. Complications assessed included disturbances of sensation, speech and swallowing, balance and gait, and strength. RESULTS: In total, 169 eligible patients were identified, including 135 (79.9%) ET and 34 (20.1%) TdPD patients. Frailty did not result in significant differences in tremor outcomes in the combined (p = 0.833), ET (p = 0.902), or TdPD (p = 0.501) cohort, or in any adverse events at the last follow-up (all p > 0.05). The combined mean follow-up was 10.3 ± 5.8 months (range 3–24 months), with cohort-specific mean follow-ups of 10.8 ± 6.0 months for ET and 8.6 ± 4.6 months for TdPD. Between the ET and TdPD cohorts, no significant differences existed in age, sex, handedness, side treated, skull density ratio, number of sonications, peak and average temperatures, energy delivered, BMI, or American Society of Anesthesiologists classification. For medical comorbidities, only hypertension was significantly different (65.9% ET, 47.1% TdPD; p = 0.043). The ET patients were significantly frailer overall, with 20.7% ET and 35.3% TdPD patients considered robust (mFI-11 score of 0), 14.8% ET and 32.4% TdPD patients prefrail (mFI-11 score of 1), 25.9% ET and 8.8% TdPD patients frail (mFI-11 score of 2), and 38.5% ET and 23.5% TdPD patients severely frail (mFI-11 score ≥ 3) (p = 0.007). CONCLUSIONS: Increasing frailty is not associated with worse outcomes, suggesting that MRgFUS may be appropriate even for frailer patients. ET patients are frailer than TdPD patients selected for MRgFUS.
- 1 October 2024
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. -1 (aop) , 1-7
Frailty and outcomes after unilateral MRI-guided focused ultrasound thalamotomy for tremor
OBJECTIVE: Frailty is recognized as an important predictor of neurointerventional outcomes. MRI-guided focused ultrasound (MRgFUS) thalamotomy is a treatment option for patients with refractory essential tremor (ET) and tremor-dominant Parkinson’s disease (TdPD). The aim of this study was to evaluate whether frailer MRgFUS thalamotomy patients had worse tremor outcomes or more complications. METHODS: The authors performed a cohort analysis of patients treated with MRgFUS between 2020 and 2023. Inclusion criteria were unilateral MRgFUS thalamotomy for ET or TdPD with available follow-up data (minimum 3-month follow-up). Frailty was assessed using the 11-item modified frailty index (mFI-11), which includes 11 medical comorbidities. Tremor outcomes were assessed using the Clinical Rating Scale for Tremor Part B. Complications assessed included disturbances of sensation, speech and swallowing, balance and gait, and strength. RESULTS: In total, 169 eligible patients were identified, including 135 (79.9%) ET and 34 (20.1%) TdPD patients. Frailty did not result in significant differences in tremor outcomes in the combined (p = 0.833), ET (p = 0.902), or TdPD (p = 0.501) cohort, or in any adverse events at the last follow-up (all p > 0.05). The combined mean follow-up was 10.3 ± 5.8 months (range 3–24 months), with cohort-specific mean follow-ups of 10.8 ± 6.0 months for ET and 8.6 ± 4.6 months for TdPD. Between the ET and TdPD cohorts, no significant differences existed in age, sex, handedness, side treated, skull density ratio, number of sonications, peak and average temperatures, energy delivered, BMI, or American Society of Anesthesiologists classification. For medical comorbidities, only hypertension was significantly different (65.9% ET, 47.1% TdPD; p = 0.043). The ET patients were significantly frailer overall, with 20.7% ET and 35.3% TdPD patients considered robust (mFI-11 score of 0), 14.8% ET and 32.4% TdPD patients prefrail (mFI-11 score of 1), 25.9% ET and 8.8% TdPD patients frail (mFI-11 score of 2), and 38.5% ET and 23.5% TdPD patients severely frail (mFI-11 score ≥ 3) (p = 0.007). CONCLUSIONS: Increasing frailty is not associated with worse outcomes, suggesting that MRgFUS may be appropriate even for frailer patients. ET patients are frailer than TdPD patients selected for MRgFUS.
- 23 March 2022
- Published by Elsevier in World Neurosurgery
- Vol. 163, e146-e155
Outcomes for Adults with Metabolic Syndrome Undergoing Elective Carotid Endarterectomy
- 23 March 2022
- Published by Elsevier in World Neurosurgery
- Vol. 163, e146-e155
Outcomes for Adults with Metabolic Syndrome Undergoing Elective Carotid Endarterectomy
- 28 July 2021
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 89 (4) , 653-663
Early Outcomes After Carotid Endarterectomy and Carotid Artery Stenting: A Propensity-Matched Cohort Analysis
BACKGROUND: Carotid endarterectomy (CEA) and carotid artery stenting (CAS) represent options to treat many patients with carotid stenosis. Although randomized trial data are plentiful, estimated rates of morbidity and mortality for both CEA and CAS have varied substantially. OBJECTIVE: To evaluate rates of adverse outcomes after CAS and CEA in a large national database. METHODS: We analyzed 84 191 adult patients undergoing elective, nonemergent CAS (n = 81 361) or CEA (n = 2830), from 2011 to 2018, in the American College of Surgeons’ National Surgical Quality Improvement Program database. Odds of adverse outcomes (30-d rates of stroke, myocardial infarction (MI), cardiac arrest, prolonged length of stay (LOS), readmission, reoperation, and mortality) were evaluated in propensity-matched (n = 2821) cohorts through logistic regression. RESULTS: In the propensity-matched cohorts, CAS had increased odds of periprocedural stroke (odds ratio [OR] 1.97, 95% CI 1.32-2.95) and decreased odds of cardiac arrest (OR 0.33, 95% CI 0.13-0.84) and 30-d reoperation (OR 0.59, 95% CI 0.44-0.80) compared to CEA. Relative odds of MI, prolonged LOS, discharge to destination other than home, 30-d readmission, or 30-d mortality were statistically similar. In the unmatched patient population, rates of adverse outcomes with CEA were constant over time; however, for CAS, rates of stroke increased over time. In both the matched and unmatched patient cohorts, patients 70 yr and older had lower rates of post-procedural stroke with CEA, but not with CAS, compared to younger patients. CONCLUSION: In a propensity-matched analysis of a large, prospectively collected, national, surgical database, CAS was associated with increased odds of periprocedural stroke, which increased over time. Rates of MI and death were not significantly different between the 2 procedures.
- 28 July 2021
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 89 (4) , 653-663
Early Outcomes After Carotid Endarterectomy and Carotid Artery Stenting: A Propensity-Matched Cohort Analysis
BACKGROUND: Carotid endarterectomy (CEA) and carotid artery stenting (CAS) represent options to treat many patients with carotid stenosis. Although randomized trial data are plentiful, estimated rates of morbidity and mortality for both CEA and CAS have varied substantially. OBJECTIVE: To evaluate rates of adverse outcomes after CAS and CEA in a large national database. METHODS: We analyzed 84 191 adult patients undergoing elective, nonemergent CAS (n = 81 361) or CEA (n = 2830), from 2011 to 2018, in the American College of Surgeons’ National Surgical Quality Improvement Program database. Odds of adverse outcomes (30-d rates of stroke, myocardial infarction (MI), cardiac arrest, prolonged length of stay (LOS), readmission, reoperation, and mortality) were evaluated in propensity-matched (n = 2821) cohorts through logistic regression. RESULTS: In the propensity-matched cohorts, CAS had increased odds of periprocedural stroke (odds ratio [OR] 1.97, 95% CI 1.32-2.95) and decreased odds of cardiac arrest (OR 0.33, 95% CI 0.13-0.84) and 30-d reoperation (OR 0.59, 95% CI 0.44-0.80) compared to CEA. Relative odds of MI, prolonged LOS, discharge to destination other than home, 30-d readmission, or 30-d mortality were statistically similar. In the unmatched patient population, rates of adverse outcomes with CEA were constant over time; however, for CAS, rates of stroke increased over time. In both the matched and unmatched patient cohorts, patients 70 yr and older had lower rates of post-procedural stroke with CEA, but not with CAS, compared to younger patients. CONCLUSION: In a propensity-matched analysis of a large, prospectively collected, national, surgical database, CAS was associated with increased odds of periprocedural stroke, which increased over time. Rates of MI and death were not significantly different between the 2 procedures.